Fe3S4 nanoparticles for arterial inflammation therapy: Integration of magnetic hyperthermia and photothermal treatment
Fe3S4 nanoparticles for arterial inflammation therapy: Integration of magnetic hyperthermia and photothermal treatment
复制标题
Fe3S4 纳米粒子用于动脉炎症治疗：磁热疗和光热治疗的结合
DOI：
10.1016/j.apmt.2019.100457
复制
发表时间：
2020-03-01
影响因子：
8.3
通讯作者：
Lu, Xinwu
中科院分区：
文献类型：
--
作者：
Liu, Junchao;Guo, Xin;Lu, Xinwu
基于纳米颗粒的光热疗法在多种疾病的治疗中得到了广泛的探索。但受激光穿透能力的限制，在治疗深动脉炎症时，其治疗效率会降低，而深动脉炎症是动脉粥样硬化和血管狭窄的主要原因。磁热疗（MHT）具有突出的组织通透性，但其磁热效率相对较差。本研究合成并表征了Fe3S4纳米粒子（NPs），并证实了其将光和磁刺激转化为热的双重能力。Fe3S4 NPs还具有良好的生物相容性和良好的T2加权磁共振成像性能（52.8 mM(-1) S-1）。此外，体外实验证实了PTT和MHT联合消融炎性巨噬细胞的良好效果。Apo E-/-小鼠模型体内实验显示，PTT联合MHT可有效消除浸润性炎性巨噬细胞，进一步抑制动脉狭窄的形成。本研究认为，基于Fe3S4 NPs的PTT和MHT联合治疗可作为治疗动脉粥样硬化和血管狭窄的有效治疗策略。(C) 2019作者。Elsevier Ltd.出版。
Photothermal therapy (PTT), based on nanoparticles, has been widely explored in the treatment of multiple diseases. However, limited by laser penetration ability, its treatment efficiency can be reduced when treating deep arterial inflammation, which is the major cause of atherosclerosis and vessels stenosis. Magnetic hyperthermia (MHT) has the outstanding tissue permeability, while its magnetothermal efficiency was relatively poor. In this study, Fe3S4 nanoparticles (NPs) were synthesized and characterized, and its dual capacity to convert light and magnetic stimulation into heat was confirmed. The Fe3S4 NPs also presented superior biocompatibility and great T2 weighted magnetic resonance imaging properties (52.8 mM(-1) S-1). Besides, its excellent effect in ablating inflammatory macrophages combining PTT and MHT was verified in vitro. In vivo experiment on Apo E-/- mice models exhibited that PTT combined with MHT could effectively eliminate infiltrating inflammatory macrophages and further inhibit the formation of arterial stenosis. This study concludes that the integration of PTT and MHT based on Fe3S4 NPs can serve as an effective therapeutic strategy for the treatment of atherosclerosis and vessels stenosis. (C) 2019 The Author(s). Published by Elsevier Ltd.